Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 8/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25679835 | 0.78 | PDE10A (0.40) | ACACBPDE10ACNR2FFAR2GSK3A | |
| SCHEMBL25120593 | 0.77 | PDE10A (0.38) | ACACBPDE10ASCN10ACNR2FFAR2 | |
| SCHEMBL23611732 | 0.76 | PDE10A (0.40) | ACACBPDE10AHDAC4CNR2FFAR2 | |
| SCHEMBL25680364 | 0.75 | KDM4E (0.35) | — | |
| SCHEMBL30464221 | 0.73 | ABL1 (0.40) | ACACBSCN10ACNR2GSK3AGSK3B | |
| SCHEMBL25680300 | 0.73 | ABL1 (0.40) | ACACBSCN10ACNR2GSK3AGSK3B | |
| SCHEMBL25680315 | 0.73 | SCN10A (0.38) | ACACBSCN10AGSK3AGSK3B | |
| SCHEMBL30464194 | 0.73 | ATR (0.40) | ACACBSCN10ACNR2GSK3AGSK3B | |
| SCHEMBL25680244 | 0.73 | NAMPT (0.50) | — | |
| SCHEMBL31214575 | 0.72 | PROKR1 (0.36) | ACACBPDE10ASCN10ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | ACACB 4227/4885PDE10A 940/4885SCN10A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.